EUVIMEDEUVIMED entdecken
Open Access

Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers

Devivasha Bordoloi iD, Abhijeet J Kulkarni, Opeyemi S Adeniji iD, M Betina Pampena iD, Pratik S Bhojnagarwala iD, Shushu Zhao iD, Candice Ionescu, Alfredo Perales-Puchalt iD, Elizabeth M Parzych iD, Xizhou Zhu iD, Ali R Ali, Joel Cassel iD und 4 weitere

Science Advances · 03.11.2023 · 9 (44)

DOI: 10.1126/sciadv.adh4379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 03.11.2023. Verfasst von Devivasha Bordoloi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Biological Products, Ovarian Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer (OC) is a lethal gynecologic malignancy, with modest responses to CPI. Engagement of additional immune arms, such as NK cells, may be of value. We focused on Siglec-7 as a surface antigen for engaging this population. Human antibodies against Siglec-7 were developed and characterized. Coculture of OC cells with PBMCs/NKs and Siglec-7 binding antibodies showed NK-mediated killing of OC lines. Anti–Siglec-7 mAb (DB7.2) enhanced survival in OC-challenged mice. In addition, the combination of DB7.2 and anti–PD-1 demonstrated further improved OC killing in vitro. To use Siglec-7 engagement as an OC-specific strategy, we engineered an NK cell engager (NKCE) to simultaneously engage NK cells through Siglec-7, and OC targets through FSHR. The NKCE demonstrated robust in vitro killing of FSHR + OC, controlled tumors, and improved survival in OC-challenged mice. These studies support additional investigation of the Siglec-7 targeting approaches as important tools for OC and other recalcitrant cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsOvarian NeoplasmsFemaleHumansMiceAnimalsKiller Cells, NaturalAntigens, CDSialic Acid Binding Immunoglobulin-like Lectins

Substanzen

Biological ProductsAntigens, CDSialic Acid Binding Immunoglobulin-like Lectins

Autor:innen und Institutionen

  • Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA.
  • Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Molecular Screening and Protein Expression facility, The Wistar Institute, Philadelphia, PA, USA.
  • Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.

ORCID-Profile: Devivasha Bordoloi, Opeyemi S Adeniji, M Betina Pampena, Pratik S Bhojnagarwala, Shushu Zhao, Alfredo Perales-Puchalt, Elizabeth M Parzych, Xizhou Zhu, Joel Cassel, Rugang Zhang, Michael R Betts, Mohamed Abdel-Mohsen, David B Weiner

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS

Zitieren

APA

Bordoloi, D., Kulkarni, A. J., Adeniji, O. S., Pampena, M. B., Bhojnagarwala, P. S., Zhao, S., Ionescu, C., Perales-Puchalt, A., Parzych, E. M., Zhu, X., Ali, A. R., Cassel, J., Zhang, R., Betts, M. R., Abdel-Mohsen, M., & Weiner, D. B. (2023). Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers. Science Advances, 9(44). https://doi.org/10.1126/sciadv.adh4379

Vancouver

Bordoloi D, Kulkarni AJ, Adeniji OS, Pampena MB, Bhojnagarwala PS, Zhao S, et al. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers. Science Advances. 2023;9(44). doi:10.1126/sciadv.adh4379

BibTeX
@article{Bordoloi2023,
  author = {Bordoloi, Devivasha and Kulkarni, Abhijeet J and Adeniji, Opeyemi S and Pampena, M Betina and Bhojnagarwala, Pratik S and Zhao, Shushu and Ionescu, Candice and Perales-Puchalt, Alfredo and Parzych, Elizabeth M and Zhu, Xizhou and Ali, Ali R and Cassel, Joel and Zhang, Rugang and Betts, Michael R and Abdel-Mohsen, Mohamed and Weiner, David B},
  title = {Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {44},
  doi = {10.1126/sciadv.adh4379}
}
Kostenlos starten →